

NPCA, Clinical Effectiveness Unit

Royal College of Surgeons of England 38-43 Lincoln's Inn Fields London WC2A 3PE

E: NPCA@rcseng.ac.uk T: 020 7869 6602 @NPCA_uk

NPCA Newsletter, March 2025

The NPCA is now part of NATCAN (National Cancer Audit Collaborating Centre). As you are on the NPCA mailing list, you will **now also be included in the NATCAN newsletter mailing list**. If you do not wish to receive NATCAN newsletters, there will be the option to opt out.

State of the Nation Report published 09.01.25


On 9th January 2025, the NPCA published their second <u>State of the Nation Report</u>, including men newly diagnosed with prostate cancer between 1st January 2019 and 31st December 2023, in England and Wales.

Findings (*infographic*, *right*) include an **increase in diagnoses**, 9% in England and 26% in Wales, when compared with the previous audit period.

Updated results from the audit's performance indicators show that they were stable relative to the previous audit period.

An in depth analysis of diagnoses and treatment by age, deprivation and ethnicity revealed inequalities. In men over 50, black men had more diagnoses per 1000 men than men from other ethnic groups. White men over 85 years were more often diagnosed with stage 4 disease than younger groups.

Men living in more deprived areas and black men were less likely to receive radical treatment for high-risk/locally advanced disease.



Treatment outcomes

For men undergoing surgery between April 2022 - March 2023 in England and Wales



of men were **readmitted** within 3 months **following surgery**



or men undergoing radical treatment between September 2020 - August 2021 in England and Wales



of men experienced at least one genitourinary complication requiring a procedural/surgical intervention within two years after radical prostatectomy in England (E) and Wales (W)

10% ^E 8% w

of men experienced at least one gastrointestinal complication requiring a procedural/surgical intervention within two years after radical radiotherapy in England (E) and Wales (W)

Diagnosis and treatment by age-ethnicity-deprivation

For men diagnosed between January 2021 - December 2023 in England

Across all age groups over 50 years, black populations had more diagnoses per 1000 men than other ethnicities

9 out of 10 diagnoses were in

White men ≥85 years were more often diagnosed with stage 4 cancer than younger groups

Men living in more deprived areas and black men were less likely to receive radical treatment for high-risk/locally advanced disease

The NPCA makes use of the most recently available data for each performance indicator. For disease presentation and treatment allocation, this corresponds to different time periodin England and Wales.

Recommendations focus on **improving data completeness**, specifically for TNM, PSA and Gleason Score; ensuring patients receive **evidence based care**; **reducing variation** in complication rates as well as variation between providers; and ensuring that treatment benefits and risks are balanced so that **equitable care** is **offered to all patients**.

Fifth Quarterly Report published 13.02.25

The audit's <u>latest quarterly report</u>, for people diagnosed with prostate cancer between July 2021 and June 2024 in England, has been published.

The **next quarterly report** will be published in **April 2025**, to align with the reporting schedule for all other NATCAN audits, and will mark the NPCA **transition to using an RShiny dashboard**.

Watch this space!

Communications update





The NPCA has joined Bluesky (@npca-natcan.bsky.social) and LinkedIn. Follow the NPCA there for news and updates.



212808